New! View global litigation for patent families

US6830755B2 - Method for relaxing human beings using personal care compositions - Google Patents

Method for relaxing human beings using personal care compositions Download PDF

Info

Publication number
US6830755B2
US6830755B2 US10218774 US21877402A US6830755B2 US 6830755 B2 US6830755 B2 US 6830755B2 US 10218774 US10218774 US 10218774 US 21877402 A US21877402 A US 21877402A US 6830755 B2 US6830755 B2 US 6830755B2
Authority
US
Grant status
Grant
Patent type
Prior art keywords
fragrance
personal
sensory
care
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10218774
Other versions
US20030064120A1 (en )
Inventor
Joseph Librizzi
Benjamin Carl Wiegand
Teresita Diaz
Laura McCulloch
John Hopkins
Theodore L. Barba
Anthony Joseph Leardi
Gerard William Appert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Companies Inc
Original Assignee
Johnson and Johnson Consumer Companies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/15Pinaceae (Pine family), e.g. pine or cedar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738Rosa (rose)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)

Abstract

This invention relates to a method of relaxing mammals comprising administering to said mammals a personal care composition which comprises an effective amount of a sensory fragrance that is effective in reducing cortisol levels and/or increasing sIgA levels.

Description

CROSS-REFERENCE TO RELATED APPLICATION

This Application is a continuation of U.S. application Ser. No. 09/676,876 filed on Sep. 29, 2000, which claimed the benefit of U.S. application Ser. No. 60/157,371 filed on Oct. 1, 1999, which are both incorporated by reference in their entireties herein.

FIELD OF THE INVENTION

This invention relates to administering personal care compositions to humans where said compositions contain sensory fragrances.

BACKGROUND OF THE INVENTION

Many currently marketed fragrant cosmetic products claim to have a “calming”, “stimulating” or “relaxing” benefit to the user. Typically, these products possess fragrances that are purported to deliver these benefits. To support these claims, several methods have been employed to measure the effects of fragrance on physiological parameters with varying degrees of success and unfortunately, much of the evidence for these purported benefits is the subject of folklore, rather than science.

Cortisol is an adrenocortical hormone which can be found in the blood and the saliva of human beings. Cortisol is produced in the adrenal cortex and is involved in a number of neurological events. Some have found that the level of this hormone rises when an individual is subjected to psychological and physiological stress. Kirschbaum, C. & Hellhammer, D. H., “Salivary Cortisol in Psychoendocrine Research: Recent Developments and Applications”; Psychoendocrinology, Vol.19 No. 4, 1994, pp. 313-333.

Others have found that when adults are subjected to psychological stress (practicing arithmetic under stressful conditions) that their level of stress can be monitored by their salivary cortisol. Tanizawa, “A Method for the Determination of the Anti-Stress Effects of Fragrances” JP Patent No.11-19076. The same researchers have shown that if the same individuals were exposed to certain fragrances before the stressful event, their level of salivary cortisol levels would not be as high as when they were psychologically challenged without the fragrance. Id. In this study, the subjects were of the age where they could perform arithmetic calculations. In addition this study showed that not all fragrances were effective at reducing the stress induced release of cortisol. Fragrances with lavender oil or mint oil successfully lowered cortisol levels, while the fragrance with skatole had the opposite effect.

Aside from cortisol levels, there are other indicators that correlate with stress levels in human beings, such as secretory immunoglobulin A (sIgA). See EP 978273 (an increase in sIgA signifies an increase in relaxation) and Stone, et al., “Evidence that Secretory IgA antibody is associated with daily mood,” 52(5) J. Personality and Social Psychology 988-93 (1987)(“Stone”). sIgA is a secretory immunoglobulin that is found in the saliva of human beings.

It would be desirable to find other fragrance compositions that are capable of reducing stress, and in particular to find such fragrance compositions that are capable of reducing stress in children. More specifically, when children, i.e., those having an age of about 1 day to about 12 years, are subjected to stressful situations, they do not smile, they cry and they do not sleep well. It would be most advantageous for the children if there were a method of reducing these physical symptoms of stress.

SUMMARY OF THE INVENTION

This invention relates to a method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1% to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%.

Another aspect of the present invention includes a method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1 to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a method of calming mammals including humans, and in particular those having an age of from about 1 day to about 12 years, comprising administering to the mammals a personal care composition which comprises an effective amount of a sensory fragrance. The preferred age of a human who is calmed by this invention is 1 week to 5 years, more preferably 1 week to 3 years, most preferably between about 1 week to about 2 years.

As used herein “calming” refers to the psychological aspects of well being, namely the feeling of good will, relaxation and/or the absence of malice and aggravation.

As used herein, “mammals” include any of a class of warm-blooded higher vertebrates that nourish their young with milk secreted by mammary glands and have skin usually more or less covered with hair, and non-exclusively includes humans, dogs and cats.

The term “administering” refers to the (i) inhalation of a topically applied personal care composition; (ii) inhalation of the vapors which are released when a personal care composition is dissolved or dispersed in a liquid vehicle such as water, or (iii) inhalation of vapors which are released when a personal care composition is dispersed, sprayed, melted or burned.

The term “effective amount” refers to the percentage by weight of the sensory fragrance, with respect to the overall weight of the personal care composition, which is needed to create the desired response in a mammal, and in particular a human being having an age of about 1 week to about 12 years. Examples of desired responses include improved sleep, increased calmness, increased relaxation, and increased smiling. Preferably the effective amount is less than about 30%, by weight of the fragrance, more preferably between about 0.1% and about 10%, most preferably between about 0.2% and about 2%.

The “sensory fragrance” is comprised of volatile oils that may be extracted from a natural or synthetic source. The sensory fragrance may also further include other odoriferous components that may be used for purposes of improving the appeal to the consumer of the personal care compositions of the invention. The preferred sensory fragrance comprises, based upon the total weight of the sensory fragrance, from about 0.01% to about 30%, e.g., from about 0.1% to about 10%, and from about 0.1% to about 8% of the essential oils, and from about 70% to about 99.99%, e.g. from about 90% to about 99.9%, and from about 92% to about 99.9% of the other odoriferous components.

The preferred sensory fragrance is comprised of essential oils selected from one or more members of the group consisting of chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, and benzoin resin.

Typically, the essential oil portion of the sensory fragrance is comprised of, based upon the total weight of the total fragrance, from about 0.05% to about 5% chamomile, about 0.01% to about 5% rose, about 0.5% to about 30% orange, about 0.01% to about 5% tuberose, about 0.01% to about 25% sandalwood, about 0.01% to about 30% lavender, about 0.1% to about 30% cedarwood, about 0.01% to about 30% bergamot, and about 0.1% to about 15% benzoin resin. Alternatively, the essential oil portion of the sensory fragrance is comprised of, based upon the total weight of the total fragrance, from about 0.05% to about 3% chamomile, between about 0.01% to about 3% rose, between about 0.5% to about 15% orange, between about 0.01% to about 3% tuberose, between about 0.01% to about 15% sandalwood, between about 0.01% to about 15% lavender, between about 0.1% to about 30% cedarwood, between about 0.01% to about 15% bergamot, and between about 0.1% to about 10% benzoin resin. In another embodiment, the essential oil portion of the sensory fragrance is comprised of, based upon the total weight of the fragrance, from about 0.05% to about 2% chamomile, from about 0.01% to about 1.5% rose, from about 0.5% to about 10% orange, from about 0.01% to about 1.5% tuberose, from about 0.01% to about 10% sandalwood, from about 0.01% to about 10% lavender, from about 0.1% to about 30% cedarwood, from about 0.01% to about 10% bergamot, and from about 0.1% to about 5% benzoin resin.

The other odoriferous components of the sensory fragrance include but are not limited to benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, and mixtures thereof. The benzenoid materials are selected from benzyl benzoate, benzyl carbinol, benzyl salicylate, benzyl cinnamate, diethyl phthalate, phenoxy ethanol, hexahydro-4,6,6,7,8,8-hexamethylcyclopenta-γ-2-benzopyran, 7-acetyl-1,1,3,4,4,6-hexamethyltetralin, 3-(3,4-methylene dioxyphenol)-2-methyl propanol, methyl-iso-eugenol, eugenol, and mixtures thereof. The alcohol materials are selected from citronellol, alcohol C-8, alcohol C-10; alcohol C-11, alcohol C12, dipropylene glycol, linalool, geraniol, benzyl alcohol, 2-ethyl-4-(2,2,3-trimethyl-3-cyclopentene-1-yl)-2-buten-l-ol, dihydromyrcenol, and mixtures thereof. The aldehyde materials are selected from 4-(4-hydroxy-4-methylpentyl)-3-cyclohexene 1-carboxoaldehyde, p-t-butyl-α-methyidihydrocinnamic aldehyde, aldehyde C-10, aldehyde C-11, aldehyde C-12, laurinal, heliotropine, anisic aldehyde, benzyl aldehyde, and mixtures thereof. The esters materials are selected from benzyl acetate, dimethyl benzyl carbinyl acetate, ethylene brassylate, cyclopentadecanolide, linalyl acetate, benzyl proprionate, citronellyl acetate, hexyl butyrate, neryl acetate, prenyl acetate, hexyl cinnamate, oxacyclohexadecen-2-one, and mixtures thereof. The ketones materials are selected from methyl ionone, ambretone, methyl dihydro jasmonate, muscone, allyl ionone, and mixtures thereof.

The sensory fragrance may be produced by blending the selected essential oils and odoriferous components under ambient conditions until the final mixture is homogenous using equipment and methodology commonly known in the art of fragrance compounding. It is preferable to store the final sensory fragrance mixture under ambient conditions for a few hours after mixing before using it as a component of a personal care composition. The personal care compositions of the present invention may then be produced by blending the desired components with the sensory fragrance using equipment and methodology commonly known in the art of personal care product manufacture. In order to improve the solubilization of the sensory fragrance in aqueous personal care compositions, the sensory fragrance may be pre-blended with one or more of the nonionic surfactants.

“Personal care compositions” refers to personal cosmetic, toiletry, and healthcare products such as wipes, washes, baths, shampoos, gels, soaps, sticks, balms, sachets, pillows, mousses, sprays, lotions, creams, cleansing compositions, powders, oils, bath oils and other bath compositions which may be added to a bath. Personal care compositions may also include, but are not limited to, aerosols, candles, and substances that may be used with vaporizers. The aforementioned wipes, washes, baths, shampoos, gels, soaps, sticks, balms, sachets, pillows, mousses, sprays, lotions, creams, cleansing compositions, oils, bath oils, aerosols, candles and substances which may be used with vaporizers are commercially known to those who have a knowledge of preparing personal care compositions.

The preferred personal care compositions of the invention are lotions, powders, bath oils and other bath additives wherein the use of the personal care compositions of the present invention is capable of reducing the cortisol levels of a mammal by about 0.1% to about 75% after the personal care composition is administered to said mammal and/or those capable of increasing the sIgA levels of a mammal by about 10% to about 150%, preferably from about 20% to about 70%. The cortisol levels of a mammal are typically reduced within about 20 minutes to about 30 minutes after administration of the personal care composition of the present invention thereto. The sIgA levels of a mammal are typically increased within about 1 minute to about 10 minutes after administration of the personal care composition of the present invention thereto. The sIgA levels may be measured in accordance with sIgA methods known in the art such as, for example, those disclosed in Stone, which is incorporated by reference herein.

In order to achieve the desired response in a mammal, the personal care composition may be used in a dosing amount that is in accordance with the prescribed directions of the personal care composition.

Particularly, the invention includes a method of increasing smiling of a human having an age of about 1 day to about 12 years comprising administering to said human a personal care composition which comprises an effective amount of the sensory fragrance. The preferred age of a human whose smiling is increased by this invention is about 1 week to about 5 years, more preferably about 1 week to about 3 years, most preferably between about 1 week to about 2 years.

Further, the invention includes a method of reducing crying in a human having an age of about 1 day to about 12 years comprising administering to said human a personal care composition which comprises an effective amount of the sensory fragrance. The preferred age of a human whose crying is reduced by this invention is about 1 week to about 5 years, more preferably about 1 week to about 3 years, most preferably between about 1 week to about 2 years.

Still further, the invention includes a method of improving sleep behaviors in a mammal including a human and in particular a human having an age of about 1 day to about 12 years comprising administering to said mammal a personal care composition which comprises an effective amount of the sensory fragrance. The preferred age of a human whose sleep behaviors are improved by this invention is about 1 week to about 5 years, more preferably about 1 week to about 3 years, most preferably between about 1 week to about 2 years.

Yet still further, the invention includes a method of soothing a mammal, and in particular a human having an age of about 1 day to about 12 years, comprising administering to said mammal a personal care composition which comprises an effective amount of the sensory fragrance. The preferred age of a human who is soothed by this invention is about 1 week to about 5 years, more preferably about 1 week to about 3 years, most preferably between about 1 week to about 2 years. The term “soothing” as used herein, refers to bringing peace, composure, relief, or quietude to a human having an age of about 1 day to about 12 years. It is generally apparent that when children in particular are soothed, they cry less, and sleep better.

In addition, the invention includes a personal care composition comprising an effective amount of the sensory fragrance, where the sensory fragrance comprises essential oils selected from one or more members of the group consisting of chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, and benzoin resin. The preferred sensory fragrance of the invention contains the essential oils chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, and benzoin resin.

Still further, the invention includes a personal care composition comprising an effective amount of the sensory fragrance, where the sensory fragrance comprises essential oils selected from one or more members of the group consisting of chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, and benzoin resin, where said personal care composition reduces the cortisol levels of a mammal by about 0.1% to about 75%, e.g. from about 20% to about 40%, from about 10% to about 50%, or from about 15% to about 35% and/or increases the level of sIgA by about 10% to about 150%, e.g. from about 20% to about 70% or from about 40% to about 55%. Preferably, the reduction of cortisol level and the increase in IgA level are measured in the saliva of a mammal.

Another additional aspect of the invention includes a method of increasing the smiling of a human comprising administering to said human a personal care composition comprising an effective amount of the sensory fragrance wherein the sensory fragrance comprises essential oils selected from one or more members of the group consisting of chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, benzoin resin.

Still further, the invention includes a method of calming a mammal comprising administering to said human a personal care composition comprising an effective amount of the sensory fragrance wherein the sensory fragrance comprises essential oils selected from one or more members of the group consisting of chamomile, rose, orange, tuberose, sandalwood, lavender, cedarwood, bergamot, and benzoin resin, where said personal care composition reduces the cortisol levels of a mammal by about 0.1% to about 75% and/or increases the sIgA levels of a mammal by about 10% to about 150%.

One method of soothing a mammal, in particular a human having an age of 1 week to about 1 year, is via the use of the personal care composition of the present invention that is comprised of, based upon the total weight of the personal care composition, from about 98.5% mineral oil and about 1.5% of the sensory fragrance, which is preferably comprised of the following essential oils in amounts based upon the total weight of the fragrance: about 1% chamomile, about 0.75% rose, about 5% orange, about 0.5% tuberose, about 7.5% sandalwood, about 8% lavender, about 4.8% cedarwood, about 9.6% bergamot, and about 0.7.% benzoin resin. The personal care composition may be massaged or rubbed onto the skin of a human being at any time, but typically the personal care composition is administered before bedtime.

In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in the calming of human beings as well as other specialties may find other methods of practicing the invention. Those methods are deemed to be within the scope of this invention.

EXAMPLES Example 1 Preparation of Personal Care Composition A with Sensory Fragrance

Takasago Fragrance #RK-2086/1, (containing 50% benzenoid material, 25% alcohol material, 12% ester material, 7% aldehyde material, 5% essential oils, and 1% ketone material) was mixed with a cleansing surfactant composition. This cleaning surfactant composition contains sodium lauroamphodiacetate, sodium laureth-13 carboxylate, sodium trideceth sulfate, polysorbate-20, PEG-150 distearate, POE 80 sorbitan monolaurate, cocamidopropyl betaine, tetrasodium EDTA, quaternium 15, citric acid, USP, sodium chloride, and water where the percentages of components in the personal care composition are listed in Table A.

TABLE A
INCI Name % Active % (wt/wt) % Active (wt/wt)
Disodium 30 2.700 0.810
Lauroamphodiacetate
Sodium Laureth-13 70 1.350 0.945
Carboxylate
Sodium Trideceth Sulfate 30 9.000 2.700
Polysorbate-20 100 0.500 0.500
PEG-150 Distearate 100 0.700 0.700
POE 80 Sorbitan Monolaurate 72 6.000 4.320
Fragrance 100 1.000 1.000
Cocamidopropyl Betaine 30 12.50 3.750
Tetrasodium EDTA 38 0.200 0.076
Quaternium 15 100 0.049 0.049
Citric Acid, USP 100 0.200 0.20
Sodium Chloride 100 2.000 2.00
Water 0 63.80 0

Example 2 Preparation of Personal Care Composition B without Sensory Fragrance

Personal Care Composition B contains a cleaning surfactant system which contains: Disodium Lauroamphodiacetate, Sodium Laureth-13 Carboxylate, Sodium Trideceth Sulfate, Polysorbate-20, PEG-150 Distearate, POE 80 Sorbitan Monolaurate, Fragrance, Cocamidopropyl Betaine, Tetrasodium EDTA, Quaternium 15, Citric Acid, USP, Sodium Chloride, and Water in the same relative ratios as the 99% portion of Personal Care Composition A.

Example 3 Bathing Infants with Personal Compositions A and B and Determining Their Salivary Cortisol Levels

Saliva samples were taken from groups of children having an age of 1 week to 4 months and their care givers. Said saliva was tested to determine the baseline salivary cortisol levels. Subsequently, the same infants were given a bath by their caregivers using Personal Care Composition B. Saliva samples were collected 20 minutes after the bathing procedure and salivary cortisol levels were measured. This group is the control group, Group 2.

Saliva samples were taken from another group of children of a similar age. Subsequently, these children were bathed with Personal Care Composition A. Saliva samples were collected 20 minutes after the bathing procedure and salivary cortisol levels were measured. This group is the testing group, Group 1.

The changes in cortisol levels of the infants and caregivers in Group 1 and Group 2 are shown in Table I.

TABLE I
Salivary Cortisol Level Change (Post bath - Initial)
Subject Group I (% CCL***) Group 2 (% CCL)
Mother* −8.2 ± 7.02 −0.4 ± 4.3
Child** −15.4 ± 19.71 +19.6 ± 29.3
1Group 1 demonstrates a statistically significant change from initial at a 94% confidence interval.
2Group 1 demonstrates a statistically significant change from initial at a 99% confidence interval.
*Group 1 demonstrates statistically significant difference from Group 2 at 99% confidence interval
**Group 1 demonstrates statistically significant difference from Group 2 at 98% confidence interval
***“CCL” means the change in cortisol level.

Example 4 Observed Behaviors of Infants and Caregivers

Another group of 10 children and their caregivers followed the bathing procedures of Example 3. The bathing procedures were monitored on videotape. Children and their caregivers were observed and the results were tabulated in Table II.

TABLE II
Observed behavior during bath
Group 1 Group 2
Behavior (% Occurrence) (% Occurrence)
Mother Smiling 37.0 ± 25.1 16.4 ± 13.9
Mother Touching Baby2 90.2 ± 11.5 65.2 ± 20.7
Child Looking at Mother1 87.4 ± 5.9  65.0 ± 26.8
1Group 1 demonstrates statistically significant difference from Group 2 at 90% confidence interval.
2Group 1 demonstrates statistically significant difference from Group 2 at 95% confidence interval.
3Group 1 demonstrates statistically significant difference from Group 2 at 99% confidence interval.

Example 5 Sleep Behaviors after Bathing

Another group of 10 children and their caregivers followed the bathing procedure of example 3. After the bath the children were placed in a quiet place and were allowed to go to sleep. During this period, sleep measurements, including sleep delay behaviors, the latency of sleep (time until onset), sleep stages (grimacing and movements) and activity level were observed and are tabulated below.

TABLE II
Observed behavior after bath
Group 1 Group 2
Behavior (% Occurrence) (% Occurrence)
Infant in Deep Sleep3* 42.2 ± 15.8  9.4 ± 17.3
Infant Crying 28.4 ± 30.8 52.1 ± 38.7
1Group 1 demonstrates statistically significant difference from Group 2 at 90% confidence interval.
2Group 1 demonstrates statistically significant difference from Group 2 at 95% confidence interval.
3Group 1 demonstrates statistically significant difference from Group 2 at 99% confidence interval.
*By “deep sleep” it is meant that the subject infant rested in a relaxed manner with minimal grimacing and movements.

Upon review of the records for the studies performed in accordance with Examples 1 through 5, it was unclear whether or not these studies were performed in accordance with the prescribed protocol. In view of this uncertainty, similar additional studies were performed as set forth below in Examples 6-8.

Example 6 Fragranced Bath and Saliva Collection

A total of eleven male and female children having an age of about 9 to 11 years participated in a bathing study in which their respective saliva samples were collected both before and after bathing for the purpose of measuring salivary cortisol concentrations and salivary sIgA concentrations.

Immediately prior to bathing, about 1 ml of an initial saliva sample was collected from each respective child via having each child drool or spit into an independent vial. These samples were then frozen until subsequent cortisol concentration and sIgA analyses.

Each child was then asked to bathe independently for a period of 10 minutes in a bath of water having a temperature of 33° C. to 35° C. The bath had been filled to a level approximately mid way on each child's torso when seated in the bathtub. Sixty grams of the fragranced bath of Example 1 were then added to the bath.

Thirty minutes after each child had finished bathing, about 1 ml of a post-bathing saliva sample was collected from each child via having each child drool or spit into a second independent vial. This second sample was also frozen for subsequent cortisol and IgA concentration analyses.

Example 7 Bathing with Unfragranced Bath and Collection

A total of 10 male and female children having an age of about 9 to 11 years participated in a second bathing study in which their saliva samples were collected both before and after bathing for the purpose of measuring salivary cortisol concentrations and salivary sIgA concentrations. Each child repeated the procedure set forth in Example 6, with the exception that an unfragranced bath of Example 2 was added to the bath in place of the fragranced bath.

Example 8 Salivary Cortisol Testing

Saliva samples obtained from the studies of Example 6 and Example 7 were tested for cortisol concentrations by Salimetrics, LLC using a “SALI METRICS HS-CORTISOL HIGH SENSITIVITY SALIVARY CORTISOL ENZYME IMMUNOASSAY KIT” available from Salimetrics, LLC in its catalog as “Catalog No. 0101 96-Well Kit” in accordance with the instructions contained therein.

The results of the cortisol analyses for examples 7 and 8 are reported in Tables III and IV.

TABLE III
Example 6 Cortisol (μg/dl)
Panelist # Before After Change
A 0.472 0.243 −0.229
B 0.084 0.113 0.029
C 0.538 0.187 −0.351
D 0.149 0.112 −0.037
E 0.16 0.128 −0.032
F 0.134 0.13 −0.004
G 0.29 0.176 −0.114
H 0.174 0.131 −0.043
I 0.145 0.076 −0.069
J 0.274 0.214 −0.06
K 0.208 0.158 −0.05

TABLE IV
Example 8 Cortisol (μg/dl)
Panelist # Before After Change
A 0.703 0.251 −0.452
B 0.191 0.116 −0.075
C 0.128 0.12 −0.008
D 0.177 0.073 −0.104
E 0.207 0.098 −0.109
F 0.074 0.049 −0.025
G 0.202 0.097 −0.105
H 0.156 0.081 −0.075
I 0.125 0.091 −0.034
J 0.195 0.119 −0.076
K 0.147 0.087 −0.06

This Example showed that both bath products were effective at reducing the cortisol levels of the children.

Example 9 Salivary sIgA Analysis

Saliva samples obtained from the studies of Example 6 and Example 7 were tested for salivary sIgA concentrations by Salimetrics, LLC in accordance with the protocol below and the materials and protocol provided in the kit of Example 8.

After thawing the saliva samples from a temperature of −80° C., the samples were vortexed, and centrifuged at 1500×g for 15 minutes. A 1:2000 dilution of the saliva was made using the buffer solution. 100 μl of calibrators and diluted saliva samples were then added to a microtiter plate coated with polyclonal rabbit antibodies to sIgA and incubated for 1 hour, with constant shaking at room temperature. After incubation, the plate was aspirated and washed 5× with 250 μl wash buffer to remove all unbound substances. 100 μl of peroxidase-labelled anti-sIgA antibody was then added to each well on the microtiter plate. After incubating the plate for 30 minutes with constant shaking at room temperature, the contents of the plate were decanted and washed 5× with the 250 μl wash buffer to remove all unbound substances. 100 μl of tetramethylbenzidine (TMB) substrate solution was added and incubated for 15-20 minutes at room temperature with no mixing. This enzyme acted on the substrate and caused a blue color to appear in proportion to the amount of peroxidase present. 50 μl of the stop solution was then added to the wells and the OD (optical density) was read on the plate reader at 450 nm. A yellow color was formed after stop solution was added. The amount of color detected was directly proportional to the amount of sIgA present.

Using values obtained from the calibrators, a dose response curve of the optical density verses concentration was then plotted. The level of secretory IgA in each sample was then determined from this curve.

The results of the sIgA analyses for examples 6 and 7 were are reported in Tables V and VI below.

TABLE V
Example 6 slgA (μg/ml)
Panelist # Before After Change
A 275.67 145.93 −129.74
B None detected 223.31 Not applicable
C 499.59 261.58 −238.01
D 518.77 451.78 −66.99
E 408.05 124.21 −283.84
F 954.27 522.98 −431.29
G 221.64 99.33 −122.31
H 119.05 119.08 0.03
I 106.66 219.09 112.43
J 201.74 279.83 78.09
K 167.8 206.62 38.82

TABLE VI
Example 7 slgA (μg/ml)
Panelist # Before After Change
A None detected 139.32 Not applicable
B 386.33 748.7 362.37
C 92.62 120.04 27.42
D 746.25 267.14 −479.11
E 310.79 461.91 151.12
F 254.18 171.65 −82.53
G 407.92 369.79 −38.13
H 221.04 211.2 −9.84
I 687.59 194.51 −493.08
J 627.52 None detected Not applicable
K 260.37 196.3 −64.07

This Example did not reveal a consistent trend in the change of sIgA concentration. While not wishing to be bound to the theory, it was considered that the 30 minute time point for saliva collection for sIgA might have been too long from the period of exposure. Therefore, it was decided to repeat the sIgA analyses, but with a shorter time period between exposure and sIgA sampling. The results of these studies are set forth in Examples 10 to 13 below.

Example 10 Effect of Sensory Fragrance on sIgA

Approximately 1 ml of saliva was collected in vials from a total of 8 male and female adults by having each adult drool or spit into an independent vial. The samples were frozen until later analyzed for sIgA concentration.

Each adult was then asked to frequently smell an open container containing the sensory fragrance used in the composition of Example 1 over a 5 minute period. Ten minutes after the completion of smelling the container, a second saliva sample was collected from each adult in an independent vial and stored as set forth above.

Five minutes following collection of the second saliva sample, a third saliva sample was collected from each adult and stored as set forth above.

Example 11 Effect of Unfragranced Composition on sIgA

The procedure of Example 10 was repeated with a total of 8 additional male and female adults, but the sensory fragrance was replaced with the unfragranced bath composition of Example 2.

Example 12 Effect of a Bath on sIgA

Approximately 1 ml of saliva was collected in vials from a total of eight male and female adults by having each adult drool or spit into an independent vial. The samples were frozen as set forth above in Example 6 until later analyzed for sIgA concentration.

Each volunteer was then asked to bathe in a tub of warm water for a period of 15 minutes.

Ten minutes after having finished bathing, a second saliva sample was collected and stored set forth above.

Example 13 Effect of a Bath with Fragranced Bath on sIgA

Approximately 1 ml of saliva was collected in vials from a total of eight male and female adult volunteers by having each adult drool or spit into an independent vial. The samples were then frozen set forth above in Example 6 until later analyzed for sIgA concentration.

Each volunteer was then asked to bathe in a tub of warm water containing 30 g of the bath composition of Example 1 for a period of 15 minutes.

Ten minutes after having finished bathing, a second saliva sample was collected and stored in the same way as the first saliva sample.

The samples were then analyzed for sIgA as described above in Example 9. The results of the sIgA analyses for examples 10, 11, 12, and 13, respectively, are reported in Tables VII, VIII, IX, and X, respectively, below.

TABLE VII
Sensory Fragrance
Example 10 SlgA (μg/ml)
Panelist # Before After Change
1 214.35 155.25 −59.1
2 79.11 178.32 99.21
3 81.05 168.06 87.01
4 129.64 271.23 141.59
5 167.75 167.01 −0.74
6 194.94 178.18 −16.76
7 85.03 175.74 90.71
8 174.97 110.18 −64.79

TABLE VIII
No sensory fragrance
Example 11 SlgA (μg/ml)
Panelist # Before After Change
1 159.9 153.82 −6.08
2 261.33 200.93 −60.4
3 150.58 131.4 −19.18
4 469.66 208.61 −261.05
5 212.73 350.69 137.96
6 107.1 108.94 1.84
7 172.57 147.3 −25.27
8 66.29 107.93 41.64

The data in Tables VII and VIII demonstrate that the sIgA concentrations of the panelists significantly increased by an average of about 47% after each adult inhaled the sensory fragrances of the present invention. The average increase in sIgA for panelists who inhaled the unfragranced material was only about 2%. This data was found to be statistically significant at a confidence level of 85%. This Example showed that the present invention is effective in increasing sIgA concentrations, which also correlates with a reduction of stress.

TABLE IX
Bath
Example 12 slgA (μg/ml)
Panelist # Before After Change
1 201.97 113.15 −88.82
2 237.69 218.85 −18.84
3 163.75 205.96 42.21
4 488.34 115.3 −373.04
5 165.52 94.93 −70.59
6  45.44 52.63 7.19
7 116.67 86.2 −30.47
8 113.43 166.48 53.05

TABLE X
Fragranced Bath
Example 13 slgA (μg/ml)
Panelist # Before After Change
1 89.48 79.42 −10.06
2 142.61 164.79 22.18
3 NA NA NA
4 415.78 191.19 −224.59
5 219.77 254.56 34.79
6 60.8 108.38 47.58
7 70.45 56.2 −14.25
8 126.78 158.21 31.43

The data in Tables IX and X showed that the sIgA changes for the panelists who bathed in water containing the sensory fragrances of the present invention were comparable to those recorded by the panelists who bathed in the water alone.

Each of the panelists who participated in the studies of Examples 10 to 13 were also given a questionnaire regarding how they each felt after the completion of the study. More specifically, the questionnaire addressed whether or not the panelists felt good, soothed, relaxed, more at ease, less stressed, safe, comforted, and/or calm after inhaling the compositions (either alone or in a bath) of the study. The results of the questionnaire for panelists who only inhaled compositions (e.g. those of Examples 10 and 11) are shown in Table XI. The results of the questionnaire for panelists who inhaled compositions while bathing therein (e.g. those of Examples 12 and 13) are shown in Table XII.

TABLE XI
Sniff Test Percent of Panelists who agreed
Feeling Unfragranced Fragranced
Soothed 38 75
Relaxed 50 88
More At Ease 38 88
Feel Good 75 75
Less Stressed 38 75
Safe 25 25
Comforted 25 63
Calm 38 88

TABLE XII
Bath Test Percent of Panelists who agreed
Feeling Unfragranced Fragranced
Soothed 57 88
Relaxed 86 100
More At Ease 100 75
Feel Good 86 100
Less Stressed 57 100
Safe 29 38
Comforted 43 75
Calm 71 75

This example showed that the panelists who inhaled the sensory fragrances (either with or without a bath) felt better and had a more positive experience than those panelists who did not inhale the sensory fragrance. Most significantly, as shown in Table XII, all of the panelists reported to have felt relaxed, good, and less stressed after inhaling the sensory composition in a bath.

Claims (10)

What is claimed is:
1. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, wherein the sensory fragrance is comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, wherein the essential oil portion is comprised of, based upon the total weight of the sensory fragrance, from about 0.05% to about 5% chamomile and about 0.01% to about 30% lavender, and wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1% to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%.
2. The method of claim 1 wherein the essential oil portion is comprised of, based upon the total weight of the sensory fragrance, from about 0.05% to about 2% chamomile and about 0.01% to about 10% lavender.
3. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, wherein the sensory fragrance is comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, wherein the essential oil portion is comprised of, based upon the total weight of the sensory fragrance, from about 0.01% to about 1.5% rose, and wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1% to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%.
4. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1% to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a shampoo.
5. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1% to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a powder.
6. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150% wherein the personal care composition is a shampoo.
7. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a wash or bath.
8. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a powder.
9. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a lotion.
10. A method of relaxing a mammal comprising administering to said mammal a personal care composition which comprises an effective amount of a sensory fragrance, the sensory fragrance being comprised of, based upon the total weight of the sensory fragrance, from about 0.1% to about 8% of an essential oil portion and from about 92% to about 99.9% of an odoriferous portion, the odoriferous portion containing one or more benzenoid materials, alcohol materials, ester materials, aldehyde materials, ketone materials, or mixtures thereof, wherein the personal care composition is capable of reducing the cortisol level of the mammal by about 0.1to about 75% and/or increasing the sIgA level of the mammal by about 10% to about 150%, wherein the personal care composition is a wipe.
US10218774 1999-10-01 2002-08-14 Method for relaxing human beings using personal care compositions Expired - Fee Related US6830755B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15737199 true 1999-10-01 1999-10-01
US67687600 true 2000-09-29 2000-09-29
US10218774 US6830755B2 (en) 1999-10-01 2002-08-14 Method for relaxing human beings using personal care compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10218774 US6830755B2 (en) 1999-10-01 2002-08-14 Method for relaxing human beings using personal care compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US67687600 Continuation 2000-09-29 2000-09-29

Publications (2)

Publication Number Publication Date
US20030064120A1 true US20030064120A1 (en) 2003-04-03
US6830755B2 true US6830755B2 (en) 2004-12-14

Family

ID=22563438

Family Applications (1)

Application Number Title Priority Date Filing Date
US10218774 Expired - Fee Related US6830755B2 (en) 1999-10-01 2002-08-14 Method for relaxing human beings using personal care compositions

Country Status (8)

Country Link
US (1) US6830755B2 (en)
EP (1) EP1218023B8 (en)
JP (1) JP2003510365A (en)
CN (1) CN1379678A (en)
CA (1) CA2387703A1 (en)
DE (2) DE60025233T2 (en)
ES (1) ES2258479T3 (en)
WO (1) WO2001024807A3 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225095A1 (en) * 2002-02-08 2003-12-04 Mcculloch Laura Method of affecting sleep and sleep-related behaviors
US20040033279A1 (en) * 2002-08-15 2004-02-19 Warrenburg William Stephen Process for effecting the relaxation of muscles of a human by means of fragrance
US20050101886A1 (en) * 2001-03-27 2005-05-12 Kazunori Shimagami Method for cosmetic operation
US20060140903A1 (en) * 2000-05-10 2006-06-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
US20060193898A1 (en) * 2005-02-25 2006-08-31 Norman Joshua J Line up of wipes products incorporating targeted sensory elements
US20070122460A1 (en) * 2005-11-28 2007-05-31 Yvonne Daily Hot-flash wipes and clothing
US20070141179A1 (en) * 2003-03-03 2007-06-21 Benjamin Wiegand Methods for alleviating symptoms associated with menopause using sensory regimen
US20070251851A1 (en) * 2006-05-01 2007-11-01 Warren Adam M Array of multi-staged cleaning wipes
US20090222305A1 (en) * 2008-03-03 2009-09-03 Berg Jr Charles John Shopper Communication with Scaled Emotional State
US20120040028A1 (en) * 2008-12-03 2012-02-16 Christine Marie Baier Compositions And Methods For Promoting A Relaxation State
US8834436B2 (en) 2000-12-12 2014-09-16 The Procter & Gamble Company Merchandise display system for identifying disposable absorbent article configurations for wearers
US9254228B2 (en) 2007-07-24 2016-02-09 The Procter & Gamble Company Array of disposable absorbent articles having a sequence of graphics corresponding to a wearer's stages of development
US9783325B1 (en) 2010-08-07 2017-10-10 Christy Booth Hierholzer Bath water enhancing packet and method of use
US9907709B2 (en) 2014-05-08 2018-03-06 The Procter & Gamble Company Length-to-waist silhouettes of adult disposable absorbent articles and arrays

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146469A1 (en) * 2000-12-20 2002-10-10 Benjamin Wiegand Methods for reducing chronic stress in mammals
WO2003055455A1 (en) * 2001-12-21 2003-07-10 Rhodia Inc. Combined stable cationic and anionic surfactant compositions
CN1845983A (en) * 2003-09-05 2006-10-11 株式会社资生堂 Perfume composition for temperature sense control, sense control article, method of sense control and perfume map
EP1778361A4 (en) 2004-07-29 2012-04-04 Reeve Tammy Rene Antimicrobial and/or antiviral composition and to methods for preparing and administering same
GB0505702D0 (en) * 2005-03-18 2005-04-27 Quest Int Serv Bv Perfume compositions
US20070207220A1 (en) * 2006-03-01 2007-09-06 Kathryn Luedtke Method for improving sleep behaviors
KR101484534B1 (en) * 2009-05-19 2015-01-21 (주)아모레퍼시픽 Fragrance composition having sound sleep effect
US20120004498A1 (en) * 2010-06-16 2012-01-05 New York University Device and method for reducing tension and stress in a subject
CN103356018A (en) * 2013-06-28 2013-10-23 江苏中新资源集团有限公司 Antibacterial health protection pillow core

Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2191878A1 (en) 1972-07-13 1974-02-08 Touzet Albert Freshening cosmetic for tired legs - contg vegetable extracts and essential oils
US4013417A (en) 1974-08-09 1977-03-22 Biomedix A.G. Analyzer for the determination of hemoglobin and other related compounds in whole blood and hemoglobin solutions
US4375421A (en) 1981-10-19 1983-03-01 Lever Brothers Company Viscous compositions containing amido betaines and salts
DE3445547A1 (en) 1983-12-23 1985-07-04 Wilfried Fischer Acoustic stimulator for relaxation therapy
US4556557A (en) 1980-12-06 1985-12-03 Dietrich Reichert Method and composition for combating snoring, and the use of surface active substances for the preparation of said composition
US4597885A (en) * 1985-01-02 1986-07-01 Pharmacaps, Inc. Encapsulated foaming bath composition
US4657690A (en) 1983-04-15 1987-04-14 L'oreal Washing and foaming composition based on non-ionic surface-active agents and anionic polymers
US4664835A (en) 1983-04-15 1987-05-12 L'oreal Washing and foaming composition based on surface-active agents and anionic polymers
US4670264A (en) 1984-11-14 1987-06-02 International Flavors & Fragrances Inc. Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
US4671959A (en) 1984-11-14 1987-06-09 Yale University Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
JPH01134688A (en) 1987-11-20 1989-05-26 Toshiba Corp Portable electronic device system
US4877322A (en) 1987-04-30 1989-10-31 Eyedentify, Inc. Method and apparatus for measuring blood oxygen levels in selected areas of the eye fundus
EP0347306A1 (en) 1988-06-14 1989-12-20 L'oreal Perfumed composition having a continuous aqueous phase and possessing a high concentration of perfume
US5009813A (en) 1986-11-28 1991-04-23 Kao Corporation Composition for hair treatment agent
US5063062A (en) 1989-09-27 1991-11-05 D. Greenspan Cleaning compositions with orange oil
JPH03284619A (en) 1990-03-30 1991-12-16 Earth Chem Corp Ltd Bathing agent composition
JPH0477416A (en) 1990-07-20 1992-03-11 Sogo Insatsu Kogei Kk Bathing agent
US5124078A (en) 1989-09-14 1992-06-23 Joh. A. Benckiser Gmbh Extra mild shower gel or hair shampoo formulation
US5275761A (en) 1992-04-15 1994-01-04 Helene Curtis, Inc. Conditioning shampoo composition and method of preparing and using the same
US5284603A (en) 1992-06-03 1994-02-08 Colgate Palmolive Co. Gelled detergent composition having improved skin sensitivity
WO1994007461A1 (en) 1992-09-29 1994-04-14 Givaudan-Roure (International) S.A. Perfume compositions
JPH06104621A (en) 1992-09-24 1994-04-15 Tokimec Inc Antenna directivity device
US5304112A (en) 1991-10-16 1994-04-19 Theresia A. Mrklas Stress reduction system and method
CA2153313A1 (en) 1993-01-23 1994-08-04 Michel Joseph Giret Cleansing compositions
CA2155766A1 (en) 1993-02-11 1994-08-18 Christopher David Leahy Cleansing compositions
US5350774A (en) 1990-06-12 1994-09-27 Cathy Palou Therapeutic preparation for topical application to the skin
CA2127657A1 (en) 1993-07-09 1995-01-10 Rita Erilli High foaming nonionic surfactant based liquid detergent
CA2127348A1 (en) 1993-07-09 1995-01-10 Rita Erilli High foaming nonionic surfactant based liquid detergent
CA2167174A1 (en) 1993-07-13 1995-01-26 Michael John Robert White Surfactant-containing compositions
US5403263A (en) 1992-05-21 1995-04-04 P.I.P. Surgical Audiotape Series, Inc. Method of reducing the recovery time and stress associated with surgery
US5403587A (en) 1993-04-22 1995-04-04 Eastman Kodak Company Disinfectant and sanitizing compositions based on essential oils
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
EP0681832A2 (en) 1994-05-11 1995-11-15 Hüls Aktiengesellschaft Aqueous viscoelastic surfactant solutions for skin and hair cleaning
US5497771A (en) 1993-04-02 1996-03-12 Mipm Mammendorfer Institut Fuer Physik Und Medizin Gmbh Apparatus for measuring the oxygen saturation of fetuses during childbirth
WO1996012468A1 (en) 1994-10-20 1996-05-02 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
WO1996025389A1 (en) 1995-02-16 1996-08-22 Henkel Kommanditgesellschaft Auf Aktien Low-viscosity aqueous concentrates of betaine tensides
FR2730634A1 (en) 1995-02-17 1996-08-23 Khayat Hanna Cosmetic base contg. plant extracts e.g. ivy, mallow, elder and valerian
CA2216964A1 (en) 1995-04-04 1996-10-10 Imperial Chemical Industries Plc Surfactant compositions
JP2548074B2 (en) 1992-08-05 1996-10-30 ローヌ−プーラン・シミ Cosmetic formulations containing suspended water-insoluble particles
US5578312A (en) 1993-05-05 1996-11-26 Parrinello; Vincene M. Skin care system and method for improving moisture retention in skin
US5597406A (en) 1993-11-02 1997-01-28 Henkel Corporation Method of thickening aqueous formulations
US5597407A (en) 1993-11-02 1997-01-28 Henkel Corporation Method of thickening aqueous formulations
WO1997003646A1 (en) 1995-07-21 1997-02-06 Cussons (International) Limited Cleaning composition
US5607980A (en) 1995-07-24 1997-03-04 The Procter & Gamble Company Topical compositions having improved skin feel
US5614553A (en) 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
WO1997028785A1 (en) 1996-02-09 1997-08-14 The Procter & Gamble Company Photoprotective compositions
JPH09227399A (en) 1996-02-27 1997-09-02 Pola Chem Ind Inc Suppressant for secretion of adrenocortical hormone
JPH09227400A (en) 1996-02-28 1997-09-02 Pola Chem Ind Inc Suppressant for secretion of adrenocortical hormone
WO1997032560A1 (en) 1996-03-05 1997-09-12 The Procter & Gamble Company Skin care compositions
US5711899A (en) 1988-12-23 1998-01-27 Henkel Kommanditgesellschaft Auf Aktien Free flowing pearlescent concentrate
US5716919A (en) 1995-05-09 1998-02-10 The Andrew Jergens Company Mild cleansing formulation with a hydroxy-containing compound, a nonionic surfactant and an anionic surfactant
WO1998008846A1 (en) 1996-08-27 1998-03-05 Pfizer Inc. Substituted 6,6-hetero-bicyclic derivatives
EP0841061A2 (en) 1996-11-07 1998-05-13 Kao Corporation Cosmetic compositions comprising an amide derivative
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5771261A (en) 1995-09-13 1998-06-23 Anbar; Michael Telethermometric psychological evaluation by monitoring of changes in skin perfusion induced by the autonomic nervous system
US5789953A (en) 1996-05-29 1998-08-04 Integrated Device Technology, Inc. Clock signal generator providing non-integer frequency multiplication
US5792739A (en) 1996-04-24 1998-08-11 Lever Brothers Company, Division Of Conopco, Inc. Liquid compositions comprising hydrophobically modified polyalkylene glycols as mildness actives
US5804538A (en) 1996-06-20 1998-09-08 The Procter & Gamble Company Perfume delivery systems in liquid personal cleansing compositions
US5849310A (en) 1994-10-20 1998-12-15 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5855884A (en) 1995-11-27 1999-01-05 Kos Pharmaceuticals, Inc. Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
JPH1119076A (en) 1997-07-07 1999-01-26 Pola Chem Ind Inc Measuring method for anti-stress effect of fragrance
JPH1123579A (en) 1997-07-07 1999-01-29 Pola Chem Ind Inc Evaluating method for massage
JPH1134688A (en) 1997-07-15 1999-02-09 Omron Corp System for monitoring mind and body information of driver engaging in vehicle-driving work and system for controlling safety operation
US5871757A (en) 1993-10-18 1999-02-16 Scotia Holdings Plc Stabilization of polyunsaturates
EP0713860B1 (en) 1994-11-22 1999-03-10 Rhodia Limited Process for the preparation of amphoacetate surfactants
US5891427A (en) * 1996-04-08 1999-04-06 Mettler; Leo Vitaminized air freshner and room deodorizer
US5904916A (en) 1996-03-05 1999-05-18 Hirsch; Alan R. Use of odorants to alter learning capacity
US5910477A (en) 1994-05-31 1999-06-08 The Procter & Gamble Company Viscous cleaning compositions with improved foam collapse
WO1999031511A1 (en) 1997-12-17 1999-06-24 Stichting Instituut Voor Dierhouderij En Diergezondheid Immunoassay for hormone detection
US5916576A (en) 1997-05-30 1999-06-29 Amway Corporation Method of scavenging free radicals using orange extract
US5922331A (en) 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5958462A (en) 1997-05-23 1999-09-28 Mclean; Linsey Therapeutic bath salts and method of use
US5980925A (en) 1997-12-30 1999-11-09 Ethicon, Inc. High glycerin containing anti-microbial cleansers
EP0978273A1 (en) 1998-08-04 2000-02-09 Shiseido Company Limited Beauty method
EP0983990A2 (en) 1998-09-04 2000-03-08 Givaudan Roure (International) S.A. Ketones useful as precursors for organoleptic compounds
JP2000275248A (en) 1999-03-24 2000-10-06 Agency Of Ind Science & Technol Chronic stress judging method, its device, recording medium and judgment sheet
US6134460A (en) 1988-11-02 2000-10-17 Non-Invasive Technology, Inc. Spectrophotometers with catheters for measuring internal tissue
EP1082960A2 (en) 1999-08-27 2001-03-14 Pfizer Products Inc. Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm
US6244265B1 (en) 1997-01-29 2001-06-12 Peter J. Cronk Adhesively applied external nasal strips and dilators containing medications and fragrances
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
WO2001098442A1 (en) 2000-06-20 2001-12-27 Shiseido Co., Ltd. Stress-relieving perfumes and stress-relieving perfume compositions containing the same
EP1198995A1 (en) 2000-10-17 2002-04-24 Laboratoires Robert Schwartz Anti-stress composition for incorporation in nutritional carriers
JP3284619B2 (en) 1992-02-04 2002-05-20 株式会社デンソー Air conditioner
WO2002049629A2 (en) 2000-12-20 2002-06-27 Johnson & Johnson Consumer Companies, Inc. Methods for reducing chronic stress in mammals
WO2002049600A1 (en) 2000-12-20 2002-06-27 Quest International B.V. Perfume compositions
US20020111529A1 (en) 2001-02-14 2002-08-15 Allen Licht Spa capsule
WO2002062198A2 (en) 2000-12-20 2002-08-15 Johnson & Johnson Consumer Companies, Inc. Methods for measuring stress in mammals
US6524626B2 (en) 1999-04-23 2003-02-25 E Excel International, Inc. Ginseng berry topical products
JP4077416B2 (en) 2004-02-24 2008-04-16 株式会社東芝 Air defense system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01185267A (en) * 1988-01-19 1989-07-24 Geran Kaihatsu Kenkyusho:Kk New inhalator

Patent Citations (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2191878A1 (en) 1972-07-13 1974-02-08 Touzet Albert Freshening cosmetic for tired legs - contg vegetable extracts and essential oils
US4013417A (en) 1974-08-09 1977-03-22 Biomedix A.G. Analyzer for the determination of hemoglobin and other related compounds in whole blood and hemoglobin solutions
US4668513A (en) 1980-12-06 1987-05-26 Dietrich Reichert Method for combating snoring
US4556557A (en) 1980-12-06 1985-12-03 Dietrich Reichert Method and composition for combating snoring, and the use of surface active substances for the preparation of said composition
US4375421A (en) 1981-10-19 1983-03-01 Lever Brothers Company Viscous compositions containing amido betaines and salts
US4657690A (en) 1983-04-15 1987-04-14 L'oreal Washing and foaming composition based on non-ionic surface-active agents and anionic polymers
US4664835A (en) 1983-04-15 1987-05-12 L'oreal Washing and foaming composition based on surface-active agents and anionic polymers
DE3445547A1 (en) 1983-12-23 1985-07-04 Wilfried Fischer Acoustic stimulator for relaxation therapy
US4670264A (en) 1984-11-14 1987-06-02 International Flavors & Fragrances Inc. Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
US4671959A (en) 1984-11-14 1987-06-09 Yale University Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
US4597885A (en) * 1985-01-02 1986-07-01 Pharmacaps, Inc. Encapsulated foaming bath composition
US5009813A (en) 1986-11-28 1991-04-23 Kao Corporation Composition for hair treatment agent
US4877322A (en) 1987-04-30 1989-10-31 Eyedentify, Inc. Method and apparatus for measuring blood oxygen levels in selected areas of the eye fundus
JPH01134688A (en) 1987-11-20 1989-05-26 Toshiba Corp Portable electronic device system
EP0347306A1 (en) 1988-06-14 1989-12-20 L'oreal Perfumed composition having a continuous aqueous phase and possessing a high concentration of perfume
US5079227A (en) 1988-06-14 1992-01-07 L'oreal Perfume composition, with a continuous aqueous phase, having a high concentration of perfume
US6134460A (en) 1988-11-02 2000-10-17 Non-Invasive Technology, Inc. Spectrophotometers with catheters for measuring internal tissue
US5711899A (en) 1988-12-23 1998-01-27 Henkel Kommanditgesellschaft Auf Aktien Free flowing pearlescent concentrate
US5124078A (en) 1989-09-14 1992-06-23 Joh. A. Benckiser Gmbh Extra mild shower gel or hair shampoo formulation
US5063062A (en) 1989-09-27 1991-11-05 D. Greenspan Cleaning compositions with orange oil
JPH03284619A (en) 1990-03-30 1991-12-16 Earth Chem Corp Ltd Bathing agent composition
JP2973368B2 (en) 1990-03-30 1999-11-08 アース製薬株式会社 Bath composition
US5350774A (en) 1990-06-12 1994-09-27 Cathy Palou Therapeutic preparation for topical application to the skin
US5614553A (en) 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
JPH0477416A (en) 1990-07-20 1992-03-11 Sogo Insatsu Kogei Kk Bathing agent
US5304112A (en) 1991-10-16 1994-04-19 Theresia A. Mrklas Stress reduction system and method
JP3284619B2 (en) 1992-02-04 2002-05-20 株式会社デンソー Air conditioner
US5275761A (en) 1992-04-15 1994-01-04 Helene Curtis, Inc. Conditioning shampoo composition and method of preparing and using the same
US5403263A (en) 1992-05-21 1995-04-04 P.I.P. Surgical Audiotape Series, Inc. Method of reducing the recovery time and stress associated with surgery
US5284603A (en) 1992-06-03 1994-02-08 Colgate Palmolive Co. Gelled detergent composition having improved skin sensitivity
JP2548074B2 (en) 1992-08-05 1996-10-30 ローヌ−プーラン・シミ Cosmetic formulations containing suspended water-insoluble particles
JPH06104621A (en) 1992-09-24 1994-04-15 Tokimec Inc Antenna directivity device
WO1994007461A1 (en) 1992-09-29 1994-04-14 Givaudan-Roure (International) S.A. Perfume compositions
CA2153313A1 (en) 1993-01-23 1994-08-04 Michel Joseph Giret Cleansing compositions
CA2155766A1 (en) 1993-02-11 1994-08-18 Christopher David Leahy Cleansing compositions
US5497771A (en) 1993-04-02 1996-03-12 Mipm Mammendorfer Institut Fuer Physik Und Medizin Gmbh Apparatus for measuring the oxygen saturation of fetuses during childbirth
US5403587A (en) 1993-04-22 1995-04-04 Eastman Kodak Company Disinfectant and sanitizing compositions based on essential oils
US5578312A (en) 1993-05-05 1996-11-26 Parrinello; Vincene M. Skin care system and method for improving moisture retention in skin
CA2127348A1 (en) 1993-07-09 1995-01-10 Rita Erilli High foaming nonionic surfactant based liquid detergent
CA2127657A1 (en) 1993-07-09 1995-01-10 Rita Erilli High foaming nonionic surfactant based liquid detergent
CA2167174A1 (en) 1993-07-13 1995-01-26 Michael John Robert White Surfactant-containing compositions
US5871757A (en) 1993-10-18 1999-02-16 Scotia Holdings Plc Stabilization of polyunsaturates
US5597406A (en) 1993-11-02 1997-01-28 Henkel Corporation Method of thickening aqueous formulations
US5597407A (en) 1993-11-02 1997-01-28 Henkel Corporation Method of thickening aqueous formulations
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
EP0681832A2 (en) 1994-05-11 1995-11-15 Hüls Aktiengesellschaft Aqueous viscoelastic surfactant solutions for skin and hair cleaning
US5965502A (en) 1994-05-11 1999-10-12 Huels Aktiengesellschaft Aqueous viscoelastic surfactant solutions for hair and skin cleaning
US5910477A (en) 1994-05-31 1999-06-08 The Procter & Gamble Company Viscous cleaning compositions with improved foam collapse
US5849310A (en) 1994-10-20 1998-12-15 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5540853A (en) 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
WO1996012468A1 (en) 1994-10-20 1996-05-02 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
EP0713860B1 (en) 1994-11-22 1999-03-10 Rhodia Limited Process for the preparation of amphoacetate surfactants
WO1996025389A1 (en) 1995-02-16 1996-08-22 Henkel Kommanditgesellschaft Auf Aktien Low-viscosity aqueous concentrates of betaine tensides
FR2730634A1 (en) 1995-02-17 1996-08-23 Khayat Hanna Cosmetic base contg. plant extracts e.g. ivy, mallow, elder and valerian
CA2216964A1 (en) 1995-04-04 1996-10-10 Imperial Chemical Industries Plc Surfactant compositions
US5716919A (en) 1995-05-09 1998-02-10 The Andrew Jergens Company Mild cleansing formulation with a hydroxy-containing compound, a nonionic surfactant and an anionic surfactant
WO1997003646A1 (en) 1995-07-21 1997-02-06 Cussons (International) Limited Cleaning composition
US5607980A (en) 1995-07-24 1997-03-04 The Procter & Gamble Company Topical compositions having improved skin feel
US5771261A (en) 1995-09-13 1998-06-23 Anbar; Michael Telethermometric psychological evaluation by monitoring of changes in skin perfusion induced by the autonomic nervous system
US5855884A (en) 1995-11-27 1999-01-05 Kos Pharmaceuticals, Inc. Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
CA2244887A1 (en) 1996-02-09 1997-08-14 The Procter & Gamble Company Photoprotective compositions
WO1997028785A1 (en) 1996-02-09 1997-08-14 The Procter & Gamble Company Photoprotective compositions
JPH09227399A (en) 1996-02-27 1997-09-02 Pola Chem Ind Inc Suppressant for secretion of adrenocortical hormone
JPH09227400A (en) 1996-02-28 1997-09-02 Pola Chem Ind Inc Suppressant for secretion of adrenocortical hormone
CA2247825A1 (en) 1996-03-05 1997-09-12 The Procter & Gamble Company Skin care compositions
WO1997032560A1 (en) 1996-03-05 1997-09-12 The Procter & Gamble Company Skin care compositions
US5904916A (en) 1996-03-05 1999-05-18 Hirsch; Alan R. Use of odorants to alter learning capacity
US5891427A (en) * 1996-04-08 1999-04-06 Mettler; Leo Vitaminized air freshner and room deodorizer
US5792739A (en) 1996-04-24 1998-08-11 Lever Brothers Company, Division Of Conopco, Inc. Liquid compositions comprising hydrophobically modified polyalkylene glycols as mildness actives
US5789953A (en) 1996-05-29 1998-08-04 Integrated Device Technology, Inc. Clock signal generator providing non-integer frequency multiplication
US5804538A (en) 1996-06-20 1998-09-08 The Procter & Gamble Company Perfume delivery systems in liquid personal cleansing compositions
WO1998008846A1 (en) 1996-08-27 1998-03-05 Pfizer Inc. Substituted 6,6-hetero-bicyclic derivatives
US5753637A (en) 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
EP0841061A2 (en) 1996-11-07 1998-05-13 Kao Corporation Cosmetic compositions comprising an amide derivative
US6244265B1 (en) 1997-01-29 2001-06-12 Peter J. Cronk Adhesively applied external nasal strips and dilators containing medications and fragrances
US5922331A (en) 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5958462A (en) 1997-05-23 1999-09-28 Mclean; Linsey Therapeutic bath salts and method of use
US5916576A (en) 1997-05-30 1999-06-29 Amway Corporation Method of scavenging free radicals using orange extract
JPH1119076A (en) 1997-07-07 1999-01-26 Pola Chem Ind Inc Measuring method for anti-stress effect of fragrance
JPH1123579A (en) 1997-07-07 1999-01-29 Pola Chem Ind Inc Evaluating method for massage
JPH1134688A (en) 1997-07-15 1999-02-09 Omron Corp System for monitoring mind and body information of driver engaging in vehicle-driving work and system for controlling safety operation
US6245769B1 (en) 1997-09-02 2001-06-12 Dupont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
WO1999031511A1 (en) 1997-12-17 1999-06-24 Stichting Instituut Voor Dierhouderij En Diergezondheid Immunoassay for hormone detection
US5980925A (en) 1997-12-30 1999-11-09 Ethicon, Inc. High glycerin containing anti-microbial cleansers
EP0978273A1 (en) 1998-08-04 2000-02-09 Shiseido Company Limited Beauty method
US6635263B2 (en) 1998-08-04 2003-10-21 Shiseido Company, Ltd. Beauty method
EP0983990A2 (en) 1998-09-04 2000-03-08 Givaudan Roure (International) S.A. Ketones useful as precursors for organoleptic compounds
JP2000275248A (en) 1999-03-24 2000-10-06 Agency Of Ind Science & Technol Chronic stress judging method, its device, recording medium and judgment sheet
US6524626B2 (en) 1999-04-23 2003-02-25 E Excel International, Inc. Ginseng berry topical products
EP1082960A2 (en) 1999-08-27 2001-03-14 Pfizer Products Inc. Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm
WO2001098442A1 (en) 2000-06-20 2001-12-27 Shiseido Co., Ltd. Stress-relieving perfumes and stress-relieving perfume compositions containing the same
EP1198995A1 (en) 2000-10-17 2002-04-24 Laboratoires Robert Schwartz Anti-stress composition for incorporation in nutritional carriers
WO2002049629A2 (en) 2000-12-20 2002-06-27 Johnson & Johnson Consumer Companies, Inc. Methods for reducing chronic stress in mammals
WO2002049600A1 (en) 2000-12-20 2002-06-27 Quest International B.V. Perfume compositions
WO2002062198A2 (en) 2000-12-20 2002-08-15 Johnson & Johnson Consumer Companies, Inc. Methods for measuring stress in mammals
US20020111529A1 (en) 2001-02-14 2002-08-15 Allen Licht Spa capsule
JP4077416B2 (en) 2004-02-24 2008-04-16 株式会社東芝 Air defense system

Non-Patent Citations (87)

* Cited by examiner, † Cited by third party
Title
"Aromachology, the Science Behind the Fragrance" article (pre Oct. 1999).
"Biology of Beauty" article (pre Oct. 1999).
"Fussy Time" Calming baby bath aromatherapy. Cited in Jun. 9, 2000 NewsEdge Article.
A. Beck, G. Brown, N. Epstein, R. Steer, An Inventory for Measuring Clinical Anxiety: Psychometric Properties, Journal of Consulting and Clinical Psychology, 1988, 893-897, vol. 56, No. 6.
A. Buske-Kirschbaum, S. Jobst, A. Wustmans, C. Kirschbaum, W. Rauh, D. Hellhammer, Attenuated Free Cortisol Response to Psychosocial Stress in Children with Atopic Dermatitis, Psychosomatic Medicine, 1997:419-426, vol. 59.
A. Delongis, S. Folkman, R. Lazarus, The Impact of Daily Stress on Health and Mood:Psychological and Social Resources as Mediators, Journal of Personality and Social Psychology, 1988:486-495, vol. 54, No. 3.
A. Garg, M. Chren, L. Sands, M. Matsui, K. Marenus, K. Feingold, P. Elias, Psychological Stress Perturbs Epidermal Permeability Barrier Homeostasis, Implications for the Pathogenesis of Stress-Associated Skin Disorders, Arch Dermatol, (Jan. 2001)53-59., vol. 137.
A. Slominski, J. Wortsman, T. Luger, R. Paus, S. Solomon, Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress, Physiological Reviews, Jul. 2000:979-1020. vol. 80, No. 3.
Abstract AU 9728425, Dobrincic. A (1998) "Soothing Calm Non Sting Herb Heal Strip . . . ".
Abstract JP 1185267 Geran Kaihatsu Kenk (1989) "Nasal Inhalation Instrument".
Anarte, M.T., et. al. "Hormonal and psychological treatment::therapeutic alternative for menopausal women?" MATURITAS, 29, pp. 203-213, 1998.
Aromatherapy Workbook, Marcel Lavabre, pp. 74,75,84, 104, 131-132,139, 152 (1990).
Arthur A. Stone, Donald S. Cox, Heiddis Valdimarsdottir and Lina Jandorf, John M. Neale, "Evidence that Secretory IgA Antibody is Associated with Daily Mood" Journal of Personality and Social Psychology, 1987, vol. 52, No. 5, 9988-993.
AU 9465919 Emili, R. et al. (1995) (Abstract).
AU 9728425 to Dobrincic, "Soathing, calming, non-stinging Herbal Strip," Abstract (Jan. 15, 1998).
Badia, P., et al., "Some Effects of Fragrances on Sleep" Compendium of Olfactory Research 1982-1994 ["Compendium"]31-36 (1994).
Barbara Carlton, "In Quest for Prettiest Baby, Parents Snap up Pricey Kid's Cosmetics" Jun. 9, 2000, NewsEdge Insight ["Carlton"].
Bottle for JOHNSON'S(R) Bedtime Bath(TM) (Oct. 1999).
Bottle for JOHNSON'S® Bedtime Bath™ (Oct. 1999).
Bottle for Origins Baby Shower(TM) wash (available before Oct. 1999).
Bottle for Origins Baby Shower™ wash (available before Oct. 1999).
C. Kirschbaum, D. Hellhammer, Salivary Cortisol in Psychobiological Research:An Overview, Neuropsychobiology 1989:150-169, vol. 22.
C. Kirschbaum, D. Hellhammer, Salivary Cortisol in Psychoneuroendocrine Research: Recent Developments and Applicantions, Psychoneuroendocrinology, 1994, 313-333, vol. 19, No. 4.
Carlton, Barbara (as cited in Wall Street Journal B1 (Jun. 9, 2000).
Clemens Kirschbaum and Dirk H. Hellhammer "Salivary Cortisol", Encyclopedia of Stress, vol. 3, pp 379-384.
Clemens Kirschbaum and Dirk Hellhammer "Salivary Cortisol in Psychoneuroendocrine Research: Recent Developments and Applications" Psychoneuroendocrinology, vol. 19, No. 4, pp. 313-333, 1994.
D. Watson, L. Clark, A. Tellegen, Development and Validation of Brief Measures of Positive and Negative Affect: The PANAS Scales, Journal of Personality and Social Psychology, 1988:1063-1070, vol. 54, No. 6.
Dember, William, et al., "Olfactory Stimulation and Sustained Attention" Compendium 39-46 (1994).
E. Aardal, A. Charlotte Holm, Cortisol in Saliva-Reference Ranges and Relation to Cortisol in Serum, European Journal Clin Chem, Clin Biochem 1995: 927-932, 33(No 12).
E. Panconsesi, G. Hautmann, Psychophysiology of Stress in Dermatology:The Psychobiologic Pattern of Psychosomatics, Dermatologic Clinics, (Jul. 1996):399-421., vol. 14, No. 3.
English-Language Abstract of FR 2191878 (1974).
EPO Search Report for EPO Appl. No. 04251206.1 dated May 14, 2004.
European Search Report, EP 03 25 0490 dated Jun. 23, 2003.
F. Dhabhar, B. McEwen, Enhancing versus suppressive effects of stress hormones on skin immune function, Proc. Natl. Acad. Sci. USA. 6(Feb. 1999):1059-1064., vol. 96.
Friess, Elisabeth et. al. "The hypothalamic-pituitary-adrenocoritcal system and sleep in man", Advances in Neuroimmunology, vol. 5, pp. 111-125, 1995.
G. Chrousos, P. Gold, The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis, Stress and Stress Disorders-Chrousos & Gold, JAMA, Mar. 4, 1992:1244-1252.vol. 267, No. 9.
Heim, Christine et. al. "The potential role of hypocortisolism is the pathophysiology of stress-related boldiy disorders". Psychoneurocrinology, vol. 25 No. 1, Jan. 2000 pp. 1-35 XP002239756.
International Search Report corresponding to Int'l Appln. PCT/US00/27035.
International Search Report dated Aug. 23, 2002 for PCT/US01/50757 (=WO 02/49629=JBP-570).
J. Kiecolt-Glaser, R. Glaser, E. Strain, J. Stout, K. Tarr, J. Holliday, C. Speicher, Modulation of Cellular Immunity in Medical Students, Journal of Behavioral Medicine, (1986):5-21., vol. 9, No. 1.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 10/012,626.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 10/012,627.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 10/353525.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 10/357648.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 10/378,384.
Johnson & Johnson Consumer Companies, Inc., U.S. patent application Ser. No. 60/256,812.
JP 01 185267 A (Geran Kaihatsu Kenk), Jul. 24, 1989 abstract.
K. Kabat-Zinn, E. Wheeler, T. Light, A. Skillings, M. Scharf, T. Cropley, D. Hosmer, J Bernhard, Influence of a Mindfulness Meditation-Based Stress Reduction Intervention on Rates of Skin Clearing in Patients with Moderate to Severe Psoriasis Undergoing Phototherapy (UVB) and Photochemotherapy(PUVA), Psychosomatic Medicine (1998):625-632, vol. 60.
Karen Douthwaite "Bringing Up Baby", Oct. 1999.
Kollias, N. et. al. "A single Parameter, Oxygenated Hemoglobin can be used to Quanitity Experimental irritant-induced inflammation", The Journal of Investigative Dermatology, vol. 104 No. 3, pp 421-424, Mar. 1995.
Leigh, Terry J. et. al, "Factor Analysis of the St. Mary's Hospital Sleep Questionnaire", SLEEP 11(5), pp. 448-453, 1988.
M. Chren, R. Lasek, S.Flocke, S. Zyzanski, improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases, Arch Dermaology, Nov. 1997:1433-1440, vol. 133.
M. Denda, T. Tsuchiya, P. Elias, K. Feingold, Stress alters cutaneous permeability barrier homeostatis, Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2000:R367-R372., vo. 278.
M. Horowtiz, N. Wilner, W. Alvarez, Impact of Event Scale: A Measure of Subjective Stress,, Psychosomatic Medicine, (May 1979):209-218, vol. 41, No. 3.
M. Morohashi, M. Toyada, Y. Luo, S. Higaki, Cutaneous Neurologic Factors are Involved in the Pathogenesis of Acne, The Journal of Investigative Dermatology:820.,2000, vol. 114 (Abstract).
M. Sulzberger, S. Zaidens,Psychogenic Factors in Dermatologic Disorders, 1948:669-685.
N. Bolger, E. Schilling, Personality and the Problems of Everyday Life: The Role of Neuroticism in Exposure and Reactivity to Daily Stressors, Journal of Personality, Sep. 1991: 355-386, 59:3.
O. Wolkowitz, V. Reus, A. Keebler, N. Nelson, M. Friedland, L. Brizendine, E. Roberts, Double-Blind Treatment of Major Depression with Dehydroepiandorsterone, Am. J. Psychiatry, Apr. 1999: 646-649, 156:4.
P. Brantley, C. Waggoner, G. Jones, N. Rappaport, A Daily Stress Inventory: Development, Reliability, and Validity, Journal of Behavioral Medicine, 1987:61-75, vol. 10, No. 1.
P. Hunt, E. Gurnell, F. Huppert, C. Richards, A. Prevost, J. Wass, J. Herbert, V. Chatterjee, Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison's Disease in a Randomized, Double Blind Trial, The Journal of Clinical Endocrinology & Metabolism, 2000:4650-4656, vol. 85, No. 12.
P. Schulz, W. Schlotz, Trierer Inventar zur Erfassung von chronischem Stress (TICS), , Diagnostica 45, Heft 1, Hogrefe Veriag Gottingen 1999: 8-19 (With English Abstract).
Package for Origins Short Cake(TM) bar (available before Oct. 1999).
Package for Origins Short Cake™ bar (available before Oct. 1999).
Package for Origins Smooth Baby(TM) oil (available before Oct. 1999).
Package for Origins Smooth Baby™ oil (available before Oct. 1999).
R. A. Dressendorfer, C. Kirschbaum, W. Rohde, F. Stahl, C.J. Strasburger, Synthesis of a Cortisol-Biotin Conjugate and Evaluation as a Tracer in an Immunoassay for Salivary Cortisol Measurement, J. Steroid Biochem, Molec. Biol. 1992, 683-692, vol. 43, No. 7.
R. Sapolsky, Why Zebras Don't Get Ulcers, W. H. Freeman and Company, New York, 1998:1-18.
S. Cohen, T.Kamarck, R. Mermelstein, A Global Measure of Perceived Stress, Journal of Health and Social Behavior 1983, 385-396, vol. 24 (Dec.).
Saintigny, Gaelle, et al., "The use of Essential Oils to Stimulate the release of relaxing substances by human Ketatinocyes" XXIst IFSCC Int'l. Congress 2000, Berlin-Proceedings.
Schmidt-Reinwald A. et. al. "The corisol response to awakening in relation to different challenge tests and a 12-hour cortisol rhythm" Life Sciences. vol. 64, No. 18, Mar. 26, 1999 p. 1653-1660 XP002239757.
Scholzen, T., Armstrong, C.A., Bunnett, N.W., Luger, T. A. , Olerud, J.E., Ansel, J.C., Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system, Experimental Dermatology, 1998:7:81-96, Denmark.
Shaw, Christine R., "The perimenopausal Hot Flash: Epidemiology, Physiology, and Treatment", The Nurse Practitioner, vol. 22, No. 3, pp. 55-66, Mar. 1997.
Shoji et. al., U.S. patent application Ser. No. 2003/005049 A1.
T.R. Cooper, H.R. Trunkfield, A.J. Zanella, W.D. Booth, An enzyme-linked Immunosorbent Assay for Cortisol in the Saliva of Man and Domestic Farm Animals, Journal of Endocrinology (1989) R13-R16.
Tausk et al., Stress and the Skin, Arch Dermatol. Jan. 2001:78-82, vol. 137.
Tube for Origins Bare Hugs(TM) cream (available before Oct. 1999).
Tube for Origins Bare Hugs™ cream (available before Oct. 1999).
Tube for Origins Diaper Service(TM) Balm (available before Oct. 1999).
Tube for Origins Diaper Service™ Balm (available before Oct. 1999).
Tube for Origins Love Me Tender(TM) lotion (available before Oct. 1999).
Tube for Origins Love Me Tender™ lotion (available before Oct. 1999).
Weil, Andrew, "Breathing-The Master Key to Self Healing" 2 CD Set (1999)-CD's attached.
William J. Cunliffe, Acne, 1989, 1-11, Martin Dunitz Ltd., UK.
Www.shiseido.co. , publicly available prior to Dec. 7, 2001.
XP002208807 & JP 11 019076 (Pola Chem Ind. Inc.) Jan. 26, 1999 abstract.
XP002208808 & JP 11 023579 (Pola Chem Ind. Inc.), Jan. 29, 1999 abstract.
XP002208946 & WO 01 98442 A (Shiseido Co. Ltd), Dec. 27, 2001 abstract.

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140903A1 (en) * 2000-05-10 2006-06-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
US9510980B2 (en) 2000-12-12 2016-12-06 The Procter & Gamble Company Merchandise display system for identifying disposable absorbent article configurations for wearers
US8834436B2 (en) 2000-12-12 2014-09-16 The Procter & Gamble Company Merchandise display system for identifying disposable absorbent article configurations for wearers
US20050101886A1 (en) * 2001-03-27 2005-05-12 Kazunori Shimagami Method for cosmetic operation
US20070149492A1 (en) * 2002-02-08 2007-06-28 Mcculloch Laura Method of affecting sleep and sleep-related behaviors
US20070275102A9 (en) * 2002-02-08 2007-11-29 Mcculloch Laura Method of affecting sleep and sleep-related behaviors
US20030225095A1 (en) * 2002-02-08 2003-12-04 Mcculloch Laura Method of affecting sleep and sleep-related behaviors
US20040033279A1 (en) * 2002-08-15 2004-02-19 Warrenburg William Stephen Process for effecting the relaxation of muscles of a human by means of fragrance
US7097863B2 (en) 2002-08-15 2006-08-29 International Flavors & Fragrances Inc. Process for effecting the relaxation of muscles of a human by means of fragrance
US20070141179A1 (en) * 2003-03-03 2007-06-21 Benjamin Wiegand Methods for alleviating symptoms associated with menopause using sensory regimen
US20060193898A1 (en) * 2005-02-25 2006-08-31 Norman Joshua J Line up of wipes products incorporating targeted sensory elements
US20070122460A1 (en) * 2005-11-28 2007-05-31 Yvonne Daily Hot-flash wipes and clothing
US7770729B2 (en) 2006-05-01 2010-08-10 The Procter & Gamble Company Array of multi-staged cleaning wipes
US20070251851A1 (en) * 2006-05-01 2007-11-01 Warren Adam M Array of multi-staged cleaning wipes
US9254228B2 (en) 2007-07-24 2016-02-09 The Procter & Gamble Company Array of disposable absorbent articles having a sequence of graphics corresponding to a wearer's stages of development
US20090222305A1 (en) * 2008-03-03 2009-09-03 Berg Jr Charles John Shopper Communication with Scaled Emotional State
US8435572B2 (en) * 2008-12-03 2013-05-07 Elc Management, Llc Compositions and methods for promoting a relaxation state
EP2373286A4 (en) * 2008-12-03 2015-03-18 Elc Man Llc Compositions and methods for promoting a relaxation state
US20120040028A1 (en) * 2008-12-03 2012-02-16 Christine Marie Baier Compositions And Methods For Promoting A Relaxation State
US9783325B1 (en) 2010-08-07 2017-10-10 Christy Booth Hierholzer Bath water enhancing packet and method of use
US9907709B2 (en) 2014-05-08 2018-03-06 The Procter & Gamble Company Length-to-waist silhouettes of adult disposable absorbent articles and arrays

Also Published As

Publication number Publication date Type
JP2003510365A (en) 2003-03-18 application
CA2387703A1 (en) 2001-04-12 application
EP1218023B1 (en) 2005-12-28 grant
WO2001024807A2 (en) 2001-04-12 application
US20030064120A1 (en) 2003-04-03 application
ES2258479T3 (en) 2006-09-01 grant
CN1379678A (en) 2002-11-13 application
DE60025233D1 (en) 2006-02-02 grant
EP1218023A2 (en) 2002-07-03 application
DE60025233T2 (en) 2006-09-21 grant
EP1218023B8 (en) 2006-05-03 grant
WO2001024807A3 (en) 2001-08-23 application

Similar Documents

Publication Publication Date Title
Kurniawan et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis.
Nohynek et al. Safety assessment of personal care products/cosmetics and their ingredients
Marks et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial
Atsumi et al. Smelling lavender and rosemary increases free radical scavenging activity and decreases cortisol level in saliva
Gunsolley A meta-analysis of six-month studies of antiplaque and antigingivitis agents
Scarr et al. Patterns of fear development during infancy
Petering et al. Trace metal content of hair
Christiansen et al. Androgen levels and components of aggressive behavior in men
Pütter et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol
Nohynek et al. Benefit and risk of organic ultraviolet filters
US5863546A (en) Cosmetic composition
Frosch et al. The soap chamber test: a new method for assessing the irritancy of soaps
Li et al. Visiting a forest, but not a city, increases human natural killer activity and expression of anti-cancer proteins
Benowitz et al. Cotinine disposition and effects
Kudielka et al. Human models in acute and chronic stress: assessing determinants of individual hypothalamus–pituitary–adrenal axis activity and reactivity
Adinoff et al. Atopic dermatitis and aeroallergen contact sensitivity
Le Roux et al. Effect of a companion dog on depression and anxiety levels of elderly residents in a long‐term care facility
Laviola et al. Peculiar response of adolescent mice to acute and chronic stress and to amphetamine: evidence of sex differences
March Disorder (ADHD)
Markowitz Pretty painful: why does tooth bleaching hurt?
Porjesz et al. Human brain electrophysiology and alcoholism
Lewis et al. Cortisol release in infants in response to inoculation
Brune et al. Iron losses in sweat
US5885593A (en) Skin care composition including cyclodextrin materials and method for treating skin therewith
Preti et al. Male axillary extracts contain pheromones that affect pulsatile secretion of luteinizing hormone and mood in women recipients

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON & JOHNSON CONSUMER COMPANIES, INC., NEW JE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKATSU, TETSUO;PARR, DEBI;REEL/FRAME:016902/0027;SIGNING DATES FROM 20050608 TO 20050727

CC Certificate of correction
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: JOHNSON & JOHNSON CONSUMER INC, NEW JERSEY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:JOHNSON & JOHNSON CONSUMER COMPANIES, LLC;JOHNSON & JOHNSON CONSUMER INC.;REEL/FRAME:036041/0605

Effective date: 20150623

Owner name: JOHNSON & JOHNSON CONSUMER COMPANIES, LLC, DELAWAR

Free format text: MERGER;ASSIGNOR:JOHNSON & JOHNSON CONSUMER COMPANIES, INC.;REEL/FRAME:036043/0978

Effective date: 20150623

AS Assignment

Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MERGED ENTITY' NEW NAME PREVIOUSLY RECORDED AT REEL: 036041 FRAME: 0605. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER & CHANGE OF NAME;ASSIGNOR:JOHNSON & JOHNSON CONSUMER COMPANIES, LLC;REEL/FRAME:036143/0449

Effective date: 20150623

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 20161214